Acute Pericarditis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Acute
pericarditis is a relatively common cause of chest pain, with approximately 5%
of patients with nonischemic chest pain being diagnosed with acute pericarditis
in the emergency department. Recurrent or relapsing pericarditis is common, is
one of the most challenging complications of acute pericarditis, and may affect
10–50% of patients. It can have infectious or non-infectious causes and is
characterized by a combination of signs (e.g., pericarp. dial rubs,
electrocardiographic changes, and pericardial effusion), symptoms (primarily
chest pain, but other symptoms such as dyspnea are possible), and usually
elevation of markers of myocardial inflammation (i.e., protein C reactive).
Simultaneous myocardial involvement is also attributed to about one-third of
patients with acute pericarditis, and it is due to overlapping etiological
agents for pericarditis and myocarditis. It is the first pericarditis attack,
generally occurring with an acute onset of symptoms. It is characterized by
chest pain, pericardial friction rub, and serial ECG changes. Chest pain is the
cardinal symptom of pericarditis, usually precordial or retrosternal, with
referral to the trapezius ridge, neck, left shoulder, or arm.
·
Acute Pericarditis incidence cases vary from
325 to 340 per 100,000 population in the USA.
Thelansis’s
“Acute Pericarditis Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2023 To 2033" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Acute
Pericarditis treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Acute Pericarditis
across 8 MM market from the centre of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm, and Unmet
needs.
Acute
Pericarditis Market Forecast Patient Based Forecast Model (MS. Excel Based
Automated Dashboard), which Data Inputs with sourcing, Market Event, and
Product Event, Country specific Forecast Model, Market uptake and patient share
uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing
scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Acute
Pericarditis, Acute Pericarditis market outlook, Acute
Pericarditis competitive landscape, Acute
Pericarditis market forecast, Thelansis, Primary
market research, KOL insights, Competitive Intelligence (CI)
Comments
Post a Comment